老年抑郁症的多组学研究进展

doi:10.3969/j.issn.1003-9198.2025.10.002

摘要/Abstract

摘要： 老年抑郁症(LLD)因发病机制复杂、临床表现异质而成为老龄化社会的重要公共卫生难题。本文系统回顾了基因组、表观基因组、转录组、蛋白质组、代谢组及多组学整合研究在LLD中的最新进展,为LLD的早期诊断、预后评估和个性化治疗提供了新的生物标志物和治疗策略。未来相关研究还需在大样本跨种族验证、生物标志物转化及衰老干预方面持续突破。

关键词: 老年人, 抑郁症, 多组学研究

Abstract: Late-life depression (LLD), characterized by complex pathogenesis and heterogeneous clinical manifestations, has become a significant public health challenge in aging societies. This review systematicly synthesizes the latest advancements in genomic, epigenomic, transcriptomic, proteomic, metabolomic, and multi-omics integrated studies on LLD, provides novel biomarkers and therapeutic strategies for early diagnosis, prognosis assessment, and personalized treatment. Future research should focus on achieving breakthroughs in large-scale cross-ethnic validation, biomarkers translation, and age-related interventions.

Key words: aged, depression, multi-omics research

中图分类号:

R 749.4

张孔雁. 老年抑郁症的多组学研究进展[J]. 实用老年医学, 2025, 39(10): 976-981.

ZHANG Kongyan. Advances in multi-omics research on depression in the elderly[J]. Practical Geriatrics, 2025, 39(10): 976-981.

参考文献

[1] ZHANG L, WANG L, YU M, et al. Hybrid representation learning for cognitive diagnosis in late-life depression over 5 years with structural MRI[J]. Med Image Anal, 2024, 94: 103135.
[2] GAO Y, SONG X N, WEN Z P, et al. The association of vitamin deficiency with depression risk in late-life depression: a review[J]. Front Nutr, 2025, 12: 1551375.
[3] UYSAL CESUR N, POYRAZ B Ç. Three-year prognosis of late-life depression in an outpatient geriatric psychiatry clinic: medical comorbidities worsen outcomes[J]. Psychiatr Q, 2023, 94(4): 675-689.
[4] LIU M, MA W, HE Y, et al. Recent progress in mass spectrometry-based metabolomics in major depressive disorder research[J]. Molecules, 2023, 28(21): 7430.
[5] CHEN C, WANG J, PAN D, et al. Applications of multi-omics analysis in human diseases[J]. MedComm, 2023, 4(4): e315.
[6] WU W, HOWARD D, SIBILLE E, et al. Differential and spatial expression meta-analysis of genes identified in genome-wide association studies of depression[J]. Transl Psychiatry, 2021, 11(1): 8.
[7] ALS T D, KURKI M I, GROVE J, et al. Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses[J]. Nat Med, 2023, 29(7): 1832-1844.
[8] MITCHELL B L, CAMPOS A I, WHITEMAN D C, et al. The Australian genetics of depression study: new risk loci and dissecting heterogeneity between subtypes[J]. Biol Psychiatry, 2022, 92(3): 227-235.
[9] HOFSTRA B M, KAS M J H, VERBEEK D S. Comprehensive analysis of genetic risk loci uncovers novel candidate genes and pathways in the comorbidity between depression and Alzheimer’s disease[J]. Transl Psychiatry, 2024, 14(1): 253.
[10] WINGO T S, GERASIMOV E S, CANON S M, et al. Alzheimer’s disease genetic burden is associated with mid-life depression among persons with normal cognition[J]. Alzheimers Dement, 2023, 19(3): 868-874.
[11] MARSHE V S, MACIUKIEWICZ M, HAUSCHILD A C, et al. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response[J]. Transl Psychiatry, 2021, 11(1): 127.
[12] BAUM M L, WIDGE A S, CARPENTER L L, et al. Pharmacogenomic clinical support tools for the treatment of depression[J]. Am J Psychiatry, 2024, 181(7): 591-607.
[13] BELVEDERI MURRI M, GRASSI L, CARUSO R, et al. Depressive symptom complexes of community-dwelling older adults: a latent network model[J]. Mol Psychiatry, 2022, 27(2): 1075-1082.
[14] LORENZO E C, KUCHEL G A, KUO C L, et al. Major depression and the biological hallmarks of aging[J]. Ageing Res Rev, 2023, 83: 101805.
[15] SATHYANARAYANAN A, MUELLER T T, ALI MONI M, et al. Multi-omics data integration methods and their applications in psychiatric disorders[J]. Eur Neuropsychopharmacol, 2023, 69: 26-46.
[16] YANG H H, HAN K M, KIM A, et al. Neuroimaging and epigenetic analysis reveal novel epigenetic loci in major depressive disorder[J]. Psychol Med, 2024, 54(10): 2585-2598.
[17] SOKOLOV A V, SCHIÖTH H B. Decoding depression: a comprehensive multi-cohort exploration of blood DNA methylation using machine learning and deep learning approaches[J]. Transl Psychiatry, 2024, 14(1): 287.
[18] HAN L K M, AGHAJANI M, PENNINX B W J H, et al. Lagged effects of childhood depressive symptoms on adult epigenetic aging[J]. Psychol Med, 2024, 54(12): 1-9.
[19] LESICKA M, DMITRZAK-WEGLARZ M, JABLONSKA E, et al. Methylation of melatonin receptors in patients with unipolar and bipolar depression[J]. Mech Ageing Dev, 2023, 211: 111776.
[20] DWIVEDI Y, ROY B, KORLA P K. Genome-wide methylome-based molecular pathologies associated with depression and suicide[J]. Neuropsychopharmacology, 2025, 50(4): 705-716.
[21] DU J, LIU N, MA L, et al. Antidepressant effect of the novel histone deacetylase-5 inhibitor T2943 in a chronic restraint stress mouse model[J]. Biomed Pharmacother, 2024, 171: 116176.
[22] TORRES-BERRÍO A, ESTILL M, PATEL V, et al. Mono-methylation of lysine 27 at histone 3 confers lifelong susceptibility to stress[J]. Neuron, 2024, 112(17): 2973-2989.e10.
[23] AL-KACHAK A, DI SALVO G, FULTON S L, et al. Histone serotonylation in dorsal raphe nucleus contributes to stress- and antidepressant-mediated gene expression and behavior[J]. Nat Commun, 2024, 15(1): 5042.
[24] LI C, XU P, HUANG Y, et al. RNA methylations in depression, from pathological mechanism to therapeutic potential[J]. Biochem Pharmacol, 2023, 215: 115750.
[25] GUO F, FAN J, LIU J M, et al. Astrocytic ALKBH5 in stress response contributes to depressive-like behaviors in mice[J]. Nat Commun, 2024, 15(1): 4347.
[26] CHEN C Y, WANG Y F, LEI L, et al. MicroRNA-specific targets for neuronal plasticity, neurotransmitters, neurotrophic factors, and gut microbes in the pathogenesis and therapeutics of depression[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2025, 136: 111186.
[27] FAN L, ZENG P, WANG X, et al. Xiaoyao Pills, a Chinese patent medicine, treats mild and moderate depression: a randomized clinical trial combined with DNA methylation analysis[J]. Phytomedicine, 2024, 130: 155660.
[28] ZENG L, FUJITA M, GAO Z, et al. A single-nucleus transcriptome-wide association study implicates novel genes in depression pathogenesis[J]. Biol Psychiatry, 2024, 96(1): 34-43.
[29] SFORZINI L, MARIZZONI M, BOTTANELLI C, et al. Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation[J]. Mol Psychiatry, 2025, 30(4): 1308-1318.
[30] GUEDES P H G, BRUSSASCO J G, MOÇO A C R, et al. A highly reusable genosensor for late-life depression diagnosis based on microRNA 184 attomolar detection in human plasma[J]. Talanta, 2023, 258: 124342.
[31] HICKS E M, SEAH C, COTE A, et al. Integrating genetics and transcriptomics to study major depressive disorder: a conceptual framework, bioinformatic approaches, and recent findings[J]. Transl Psychiatry, 2023, 13(1): 129.
[32] KANG J, YANG L, JIA T, et al. Plasma proteomics identifies proteins and pathways associated with incident depression in 46, 165 adults[J]. Sci Bull, 2025, 70(4): 573-586.
[33] SUN R, TANG M Y, YANG D, et al. C3aR in the medial prefrontal cortex modulates the susceptibility to LPS-induced depressive-like behaviors through glutamatergic neuronal excitability[J]. Prog Neurobiol, 2024, 236: 102614.
[34] PU J, LIU Y, WU H, et al. Characterizing metabolomic and proteomic changes in depression: a systematic analysis[J]. Mol Psychiatry, 2025, 30(7): 3120-3128.
[35] MA S, XIE X, DENG Z, et al. A machine learning analysis of big metabolomics data for classifying depression: model development and validation[J]. Biol Psychiatry, 2024, 96(1): 44-56.
[36] LIU Y, ZHAO W, LU Y, et al. Systematic metabolic characterization of mental disorders reveals age-related metabolic disturbances as potential risk factors for depression in older adults[J]. MedComm, 2022, 3(4): e165.
[37] AMIN N, LIU J, BONNECHERE B, et al. Interplay of metabolome and gut microbiome in individuals with major depressive disorder vs control individuals[J]. JAMA Psychiatry, 2023, 80(6): 597-609.
[38] CHEN X, WANG Y, PEI C, et al. Vacancy-driven high-performance metabolic assay for diagnosis and therapeutic evaluation of depression[J]. Adv Mater, 2024, 36(28): e2312755.
[39] VAN DER SPEK A, STEWART I D, KÜHNEL B, et al. Circulating metabolites modulated by diet are associated with depression[J]. Mol Psychiatry, 2023, 28(9): 3874-3887.
[40] O’CONNOR L M, O’CONNOR B A, LIM S B, et al. Integrative multi-omics and systems bioinformatics in translational neuroscience: a data mining perspective[J]. J Pharm Anal, 2023, 13(8): 836-850.
[41] OMRAN M M, EMAM M, GAMALELDIN M, et al. Comparative analysis of statistical and deep learning-based multi-omics integration for breast cancer subtype classification[J]. J Transl Med, 2025, 23(1): 709.
[42] BI X A, SHEN W, SHAN Y, et al. MSAFF: multi-way soft attention fusion framework with the large foundation models for the diagnosis of Alzheimer’s disease[J]. IEEE Trans Neural Netw Learn Syst, 2025: PP.
[43] PANG J, LIANG B, DING R, et al. A denoised multi-omics integration framework for cancer subtype classification and survival prediction[J]. Brief Bioinform, 2023, 24(5): bbad304.
[44] WU X, YANG X, DAI Y, et al. Single-cell sequencing to multi-omics: technologies and applications[J]. Biomark Res, 2024, 12(1): 110.
[45] CHEN M, CHENG R, HE J, et al. SMOPCA: spatially aware dimension reduction integrating multi-omics improves the efficiency of spatial domain detection[J]. Genome Biol, 2025, 26(1): 135.
[46] HARLEV D, SINGER S, GOLDSHALGER M, et al. Acoustic speech features are associated with late-life depression and apathy symptoms: preliminary findings[J]. Alzheimers Dement, 2025, 17(1): e70055.
[47] TAN J, MA C, ZHU C, et al. Prediction models for depression risk among older adults: systematic review and critical appraisal[J]. Ageing Res Rev, 2023, 83: 101803.